Underrepresentation of blacks, smokers, and obese patients in studies of monoclonal antibodies for asthma.
作者信息
Akenroye Ayobami, Keet Corinne
机构信息
Division of Pediatric Allergy and Immunology, Johns Hopkins University School of Medicine, Baltimore, Md.
Division of Pediatric Allergy and Immunology, Johns Hopkins University School of Medicine, Baltimore, Md.
出版信息
J Allergy Clin Immunol Pract. 2020 Feb;8(2):739-741.e6. doi: 10.1016/j.jaip.2019.08.023. Epub 2019 Aug 28.
Abstract
摘要
相似文献
1
Underrepresentation of blacks, smokers, and obese patients in studies of monoclonal antibodies for asthma.黑人、吸烟者和肥胖患者在哮喘单克隆抗体研究中的代表性不足。
J Allergy Clin Immunol Pract. 2020 Feb;8(2):739-741.e6. doi: 10.1016/j.jaip.2019.08.023. Epub 2019 Aug 28.
2
Association between asthma, obesity, and health behaviors in African American youth.非裔美国青少年哮喘、肥胖与健康行为之间的关联。
J Asthma. 2020 Apr;57(4):410-420. doi: 10.1080/02770903.2019.1571083. Epub 2019 Jan 31.
3
Burden of rare coding variants reveals genetic heterogeneity between obese and non-obese asthma patients in the African American population.肥胖型和非肥胖型哮喘患者在非裔美国人中的罕见编码变异负担揭示了遗传异质性。
Respir Res. 2022 May 6;23(1):116. doi: 10.1186/s12931-022-02039-0.
4
The association of overweight and obesity with spirometric values in minority children referred for asthma evaluation.因哮喘评估而接受检查的少数族裔儿童中超重和肥胖与肺功能测定值的关联。
J Asthma. 2013 Feb;50(1):56-63. doi: 10.3109/02770903.2012.744035. Epub 2012 Nov 28.
5
Vitamin D and pulmonary function in obese asthmatic children.肥胖哮喘儿童的维生素D与肺功能
Pediatr Pulmonol. 2016 Dec;51(12):1276-1283. doi: 10.1002/ppul.23485. Epub 2016 Jun 6.
6
Higher prevalence of obesity among children with asthma.哮喘儿童肥胖患病率较高。
Obesity (Silver Spring). 2012 May;20(5):1041-7. doi: 10.1038/oby.2012.5. Epub 2012 Jan 17.
7
Obesity and bronchodilator response in black and Hispanic children and adolescents with asthma.肥胖与黑人和西班牙裔哮喘儿童及青少年的支气管扩张剂反应
Chest. 2015 Jun;147(6):1591-1598. doi: 10.1378/chest.14-2689.
8
The effect of obesity on outcomes in mechanically ventilated patients in a medical intensive care unit.肥胖对医学重症监护病房中机械通气患者预后的影响。
Respiration. 2014;87(3):219-26. doi: 10.1159/000357317. Epub 2014 Jan 23.
9
Gene-based analysis identified the gene ZNF248 is associated with late-onset asthma in African Americans.基于基因的分析确定基因ZNF248与非裔美国人迟发性哮喘有关。
Ann Allergy Asthma Immunol. 2016 Jul;117(1):50-55.e2. doi: 10.1016/j.anai.2016.05.005. Epub 2016 May 27.
10
The effect of obesity on asthma incidence: moving past the epidemiologic evidence.肥胖对哮喘发病率的影响：超越流行病学证据
J Allergy Clin Immunol. 2009 Jan;123(1):96-7. doi: 10.1016/j.jaci.2008.11.003.
引用本文的文献
1
Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study.tezepelumab在美国不同严重哮喘患者群体中的有效性和安全性：PASSAGE研究的初步结果
Adv Ther. 2025 Jul;42(7):3334-3353. doi: 10.1007/s12325-025-03231-6. Epub 2025 May 19.
2
Artificial intelligence in respiratory care: perspectives on critical opportunities and challenges.呼吸护理中的人工智能：关键机遇与挑战的视角
Breathe (Sheff). 2024 Dec 10;20(3):230189. doi: 10.1183/20734735.0189-2023. eCollection 2024 Oct.
3
Obesity-related Asthma: A Pathobiology-based Overview of Existing and Emerging Treatment Approaches.肥胖相关性哮喘：基于病理生理学的现有和新兴治疗方法概述。
Am J Respir Crit Care Med. 2024 Nov 15;210(10):1186-1200. doi: 10.1164/rccm.202406-1166SO.
4
Temporal variation in the effectiveness of biologics in asthma: Effect modification by changing patient characteristics.哮喘生物制剂疗效的时间变化：改变患者特征的效应修饰。
Respir Med. 2024 Nov-Dec;234:107802. doi: 10.1016/j.rmed.2024.107802. Epub 2024 Sep 10.
5
RIAIT (Italian Registry of Allergen Immunotherapy): Protocol for a New Tool in a New Vision of Disease-Modifying Therapy for Allergists.意大利变应原免疫治疗登记处（RIAIT）：为过敏症专科医生提供疾病修饰治疗新视野下的新工具方案。
J Pers Med. 2024 Aug 12;14(8):854. doi: 10.3390/jpm14080854.
6
Race and ethnicity, not just insurance, is associated with biologics initiation in asthma and related conditions.种族和族裔，而非仅仅保险因素，与哮喘及相关病症中生物制剂的起始使用有关。
J Allergy Clin Immunol. 2025 Mar;155(3):1036-1044. doi: 10.1016/j.jaci.2024.08.001. Epub 2024 Aug 6.
7
Lung function trajectories in a cohort of patients with moderate-to-severe asthma on mepolizumab, omalizumab, or dupilumab.美泊利珠单抗、奥马珠单抗或度匹鲁单抗治疗中重度哮喘患者的肺功能轨迹。
Allergy. 2024 May;79(5):1195-1207. doi: 10.1111/all.16002. Epub 2024 Jan 2.
8
Real-world outcomes of mepolizumab treatment in severe eosinophilic asthma patients - retrospective cohort study in Slovakia.在捷克共和国重度嗜酸性粒细胞性哮喘患者中使用美泊利珠单抗治疗的真实世界结局 - 回顾性队列研究。
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2023 Sep;167(3):272-280. doi: 10.5507/bp.2023.029. Epub 2023 Jul 10.
9
Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: A target trial emulation.奥马珠单抗、美泊利珠单抗和度匹鲁单抗治疗哮喘的疗效比较：一项目标试验模拟。
J Allergy Clin Immunol. 2023 May;151(5):1269-1276. doi: 10.1016/j.jaci.2023.01.020. Epub 2023 Feb 3.
10
Biologics in severe asthma: the role of real-world evidence from registries.生物制剂在重症哮喘中的应用：来自登记处的真实世界证据的作用。
Eur Respir Rev. 2022 Jun 7;31(164). doi: 10.1183/16000617.0278-2021. Print 2022 Jun 30.
本文引用的文献
1
Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response.抗白细胞介素-5 疗法在严重嗜酸性粒细胞性哮喘患者中的临床疗效及可能的治疗反应标准。
BMC Pulm Med. 2018 Jul 18;18(1):119. doi: 10.1186/s12890-018-0689-2.
2
Omalizumab Treatment Response in a Population With Severe Allergic Asthma and Overlapping COPD.严重过敏性哮喘合并慢性阻塞性肺疾病患者的奥马珠单抗治疗反应
Chest. 2017 Jan;151(1):78-89. doi: 10.1016/j.chest.2016.09.035. Epub 2016 Oct 11.
3
Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry.奥马珠单抗治疗高合并症发生率的重度过敏性哮喘人群的疗效和应答预测因素：澳大利亚 Xolair 注册研究。
Intern Med J. 2016 Sep;46(9):1054-62. doi: 10.1111/imj.13166.
4
Obesity and bronchodilator response in black and Hispanic children and adolescents with asthma.肥胖与黑人和西班牙裔哮喘儿童及青少年的支气管扩张剂反应
Chest. 2015 Jun;147(6):1591-1598. doi: 10.1378/chest.14-2689.
5
Severe asthma in children.儿童重度哮喘
J Allergy Clin Immunol Pract. 2014 Sep-Oct;2(5):489-500. doi: 10.1016/j.jaip.2014.06.022.
6
Cluster analysis and characterization of response to mepolizumab. A step closer to personalized medicine for patients with severe asthma.聚类分析和对美泊利单抗应答的特征。为严重哮喘患者的个体化药物治疗又迈进了一步。
Ann Am Thorac Soc. 2014 Sep;11(7):1011-7. doi: 10.1513/AnnalsATS.201312-454OC.
7
Elevated sputum interleukin-5 and submucosal eosinophilia in obese individuals with severe asthma.肥胖的重症哮喘患者痰中白细胞介素-5 水平升高和黏膜下嗜酸性粒细胞增多。
Am J Respir Crit Care Med. 2013 Sep 15;188(6):657-63. doi: 10.1164/rccm.201208-1470OC.
8
Rationality and the generalization of randomized controlled trial evidence.合理性与随机对照试验证据的推广
J Eval Clin Pract. 2013 Aug;19(4):644-7. doi: 10.1111/jep.12021. Epub 2013 Jan 31.
9
Smoking and asthma: dangerous liaisons.吸烟与哮喘：危险的联姻。
Eur Respir J. 2013 Mar;41(3):716-26. doi: 10.1183/09031936.00073312. Epub 2012 Aug 16.
10
Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children.奥马珠单抗（抗 IgE）治疗城市内儿童哮喘的随机试验。
N Engl J Med. 2011 Mar 17;364(11):1005-15. doi: 10.1056/NEJMoa1009705.
Zotero 插件